

Jens Benn Sørensen
Klinisk lektor, Overlæge, dr.med., MPA
Institut for Klinisk Medicin
Postadresse:
Blegdamsvej 3
2200
København N
E-mail: jens.benn.soerensen@regionh.dk
Telefon: +45 35 45 1148

Ansættelse

Klinisk lektor

Institut for Klinisk Medicin
Københavns Universitet
København N.
31 dec. 2010 → nu

Klinisk onkologi

Københavns Universitet
1 jan. 2017 → nu

Klinisk lektor

Institut for Klinisk Medicin
Københavns Universitet
København N.
1 jan. 2011 → nu

Klinisk lektor

Institut for Klinisk Medicin
Københavns Universitet
København N.
1 feb. 2014 → 31 jan. 2024

Ph.d.-vejledningslektor

Ph.d.-studienævnet for Medicin
Københavns Universitet
København N., Danmark
1 jan. 2011 → 3 jan. 2012

Ph.d.-vejledningslektor

Bachelor- og kandidatuddannelser
Københavns Universitet
København N.
1 jan. 2011 → 8 mar. 2012

Klinisk lærer sygehus

Bachelor- og kandidatuddannelser
Københavns Universitet
København N.
1 sep. 1992 → 6 okt. 2007

Klinisk lærer sygehus

Bachelor- og kandidatuddannelser
Københavns Universitet
København N.

1 sep. 1992 → 14 maj 2008

Publikationer

UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma – A phase II randomised trial

Haakensen, V. D., Öjlert, Å. K., Thunold, S., Farooqi, S., Nowak, A. K., Chin, W. L., Grundberg, O., Szejniuk, W. M., Cedres, S., Sørensen, Jens Benn, Dalen, T. S., Lund-Iversen, M., Bjaanæs, M. & Helland, Å., 2024, I: *European Journal of Cancer*. 202, 6 s., 113973.

Artificial Intelligence for Automated DWI/FLAIR Mismatch Assessment on Magnetic Resonance Imaging in Stroke: A Systematic Review

Offersen, C. M., Sørensen, Jens Benn, Sheng, K., Carlsen, Jonathan Frederik, Langkilde, Annika Reynberg, Pai, A., Truelsen, Thomas Clement & Nielsen, Michael Bachmann, 2023, I: *Diagnostics*. 13, 12, 15 s., 2111.

Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?

Urbanska, E. M., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2023, I: *Journal of Thoracic Oncology*. 18, 3, s. e28-e29

New pathogenic germline variants identified in mesothelioma

Belcaid, L., Bertelsen, B., Wadt, Karin Anna Wallentin, Tuxen, I., Spanggaard, I., Højgaard, M., Sørensen, Jens Benn, Ravn, J., Lassen, Ulrik Niels, Nielsen, Finn Cilius, Rohrberg, K. & Westmose Yde, C., 2023, I: *Lung Cancer*. 179, 8 s., 107172.

Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De Novo MET Amplification in Patients with Metastatic EGFR-Mutated NSCLC

Urbanska, E. M., Grauslund, M., Koffeldt, P. R., Truelsen, S. L. B., Löfgren, J. O., Costa, J. C., Melchior, L. C., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2023, I: *International Journal of Molecular Sciences*. 24, 17, 25 s., 13077.

Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study

Mouritzen, M. T., Junker, K. F., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A-C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L. & 7 flere, Homann, P. H., Kristensen, E. B., Drivsholm, L. B., Bøgsted, M., Christensen, H. S., Pøhl, M. & Bjørnhart, B., 2022, I: *Acta Oncologica*. 61, 4, s. 409-416

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non-Small-Cell Lung Cancer

Urbanska, E. M., Sørensen, Jens Benn, Melchior, L. C., Costa, J. C. & Santoni Rugiu, Eric, 2022, I: *JCO Precision Oncology*. 6, 6, 6 s., e2200040.

Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study

Sørensen, Jens Benn, Horvat, P., Rosenlund, M., Kejs, A. M., Patel, D., Juarez-Garcia, A., Lacoïn, L., Daumont, M. J., Penrod, J. R., O'donnell, J. C., Brustugun, O. T. & Ekman, S., 2022, I: *Future Oncology*. 18, 2, s. 205-214 10 s.

Correlation of MET-receptor overexpression with MET gene amplification and patient outcome in malignant mesothelioma

Santoni Rugiu, Eric, Lü, M. J. S., Jakobsen, J. N., Melchior, L. C., Ravn, J. & Sørensen, Jens Benn, 2021, I: *International Journal of Molecular Sciences*. 22, 23, 20 s., 12868.

Intracranial Response of ALK⁺ Non-Small-cell Lung Cancer to Second-line Dose-escalated Brigatinib After Alectinib Discontinuation Due to Drug-induced Hepatitis and Relapse After Whole Brain Radiotherapy Followed by Stereotactic Radiosurgery

Urbanska, E. M., Santoni Rugiu, Eric, Melchior, L. C., Carlsen, Jonathan Frederik & Sørensen, Jens Benn, 2021, I: *Clinical Lung Cancer*. 22, 4, s. e528-e532 5 s.

Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study

Eide, I. J. Z., Grut, H., Helland, Å., Ekman, S., Sørensen, Jens Benn, Hansen, K. H., Grønberg, B. H., Cicenás, S., Koivunen, J. P., Mellemegaard, A. & Brustugun, O. T., 2021, I: *Acta Oncologica*. 60, 12, s. 1565-1571 7 s.

Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A. C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., Frary, J. M. C. & 5 flere, Drivsholm, L. B., Vesteghem, C., Christensen, H. S., Bjørnhart, B. & Pøhl, M., 2021, I: *Cancers*. 13, 19, 4846.

Treatment Algorithm for Advanced ALK-Rearranged NSCLC

Urbanska, E. M., Sørensen, Jens Benn & Santoni Rugiu, Eric, sep. 2020, I: *Journal of Thoracic Oncology*. 15, 9, s. e156-e157

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition

Urbanska, E. M., Sørensen, Jens Benn, Melchior, L. C., Costa, J. C. & Santoni Rugiu, Eric, 2020, I: *International Journal of Molecular Sciences (Online)*. 21, 8, 12 s., 2847.

Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance.

Santoni Rugiu, Eric, Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., Stricker, K. D., Grauslund, M. & Sørensen, Jens Benn, 1 jul. 2019, I: *Cancers*. 11, 7, 923.

18F-FDG PET/CT Findings in Disseminated Genital Herpes in an Immunocompetent Patient With Anaplastic Lymphoma Kinase Rearranged Advanced Nonsmall Cell Lung Cancer

Dejanovic, D., Amtoft, A. G., Sørensen, Jens Benn & Pøhl, M., 2019, I: *Clinical Nuclear Medicine*. 44, 5, s. e351-e352

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Scagliotti, G. V., Gaafar, R., Nowak, A. K., Nakano, T., van Meerbeeck, J., Popat, S., Vogelzang, N. J., Grosso, F., Aboelhasan, R., Jakopovic, M., Ceresoli, G. L., Taylor, P., Orlandi, F., Fennell, D. A., Novello, S., Scherpereel, A., Kuribayashi, K., Cedres, S., Sørensen, J. B., Pavlakis, N. & 6 flere, Reck, M., Velema, D., von Wangenheim, U., Kim, M., Barrueco, J. & Tsao, A. S., 2019, I: *The Lancet Respiratory Medicine*. 7, 7, s. 569-580 12 s.

Very Early Response Evaluation by PET/MR in Patients with Lung Cancer: Timing and Feasibility

Langer, N. H., Langer, Seppo W., Johannesen, H. H., Hansen, A. E., Costa, J., Klausen, T. L., Forman, Julie Lyng, Olin, A., Rasmussen, S. H., Sørensen, Jens Benn, Löfgren, J., Kjær, A. & Fischer, B. M., 2019, I: *Diagnostics*. 9, 1, 13 s., 35.

Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts

Buhl, I. K., Santoni Rugiu, Eric, Ravn, J., Hansen, A., Christensen, I. J., Jensen, T., Pratt, B., Askaa, J., Jensen, P. B., Knudsen, S. & Sørensen, Jens Benn, 22 mar. 2018, I: *PLOS ONE*. 13, 3, 18 s., e0194609.

Changing Resistance Mechanisms in Rebiopsies of ALK-Positive NSCLC During Multiple Lines of Therapy: ALK/BRAF-Mutations Followed By EMT

Urbanska, E., Melchior, L., De Stricker, K., Sørensen, Jens Benn & Rugiu, E. S., 2018, I: *Journal of Thoracic Oncology*. 13, 10, s. S946 1 s.

Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

Jakobsen, J. N., Santoni Rugiu, Eric, Grauslund, M., Melchior, L. & Sørensen, Jens Benn, 2018, I: *OncoTarget*. 9, 40, s. 26195-26208

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., Cheng, S. Y-S., Bischoff, H. G., Peled, N., Grossi, F., Jennens, R. R., Reck, M., Hui, R., Garon, E. B., Boyer, M., Rubio-Viqueira, B. & 19 flere, Novello, S., Kurata, T., Gray, J. E., Vida, J., Wei, Z., Yang, J., Raftopoulos, H., Pietanza, M. C., Garassino, M. C., KEYNOTE-189 Investigators, K. I., Boyer, M., Bray, V., Houghton, B. B., Sørensen, Jens Benn, Hansen, K. H., Stelmach, M. J., Walsh, W. V., Wrangle, J. & Wrzesinski, S. H., 2018, I: The New England Journal of Medicine. 378, 22, s. 2078-2092

Concomitant Driver Mutations in Advanced Stage Non-Small-Cell Lung Cancer of Adenocarcinoma Subtype with Activating EGFR-Mutation

Sørensen, Jens Benn, Grauslund, M., Melchior, L., Jakobsen, J. N. & Santoni Rugiu, Eric, 2017, I: Journal of Thoracic Oncology. 12, S1, s. S518-S519

Heterogeneous Resistance Mechanisms in Rebiopsies from EGFR-Mutated NSCLC: Transformation to SCLC; FGFR3 and T790M Mutations

Urbanska, E., Grauslund, M., Melchior, L., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2017, I: Journal of Thoracic Oncology. 12, 11 - S2, s. S2203

Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation

Santoni Rugiu, Eric, Grauslund, M., Melchior, L. C., Costa, J. C., Sørensen, Jens Benn & Urbanska, E. M., 2017, I: Lung Cancer. 113, s. 14-17 4 s.

Implementation of lung cancer CT screening in the Nordic countries

Pedersen, J. H., Sørensen, Jens Benn, Saghir, Z., Fløtten, Ø., Brustugun, O. T., Ashraf, H., Strand, T., Friesland, S., Koyi, H., Ek, L., Nyrén, S., Bergman, P., Jekunen, A., Nieminen, E. & Gudbjartsson, T., 2017, I: Acta Oncologica. 56, 10, s. 1249-1257

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Grosso, F., Steele, N., Novello, S., Nowak, A. K., Popat, S., Greillier, L., John, T., Leigh, N. B., Reck, M., Taylor, P., Planchard, D., Sørensen, Jens Benn, Socinski, M. A., von Wangenheim, U., Loembé, A. B., Barrueco, J., Morsli, N. & Scagliotti, G., 2017, I: Journal of Clinical Oncology. 35, 31, s. 3591-3600

The prevalence of ALK rearrangement in pulmonary adenocarcinomas in an unselected Caucasian population from a defined catchment area: impact of smoking

Skov, B. G., Clementsen, P., Larsen, Klaus Richter, Sørensen, Jens Benn & Mellempgaard, A., 2017, I: Histopathology. 70, 6, s. 889-895

Prospective blinded evaluation predicting efficacy of adjuvant cisplatin and vinorelbine by a multigene assay after radical surgery in non-small cell lung cancer

Buhl, I. K., Santoni Rugiu, Eric, Ravn, J., Hansen, A., Christensen, I. J., Jensen, T., Jensen, P. B., Askaa, J., Knudsen, S. & Sørensen, Jens Benn, 2016, I: Journal of Clinical Oncology. e20007.

High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma

Zimling, Z. G., Santoni Rugiu, Eric, Bech, C. & Sørensen, Jens Benn, dec. 2015, I: Anticancer Research. 35, 12, s. 6731-8 8 s.

Methylation-associated Silencing of microRNA-126 and its Host Gene *EGFL7* in Malignant Pleural Mesothelioma

Andersen, M., Trapani, D., Ravn, J., Sørensen, Jens Benn, Andersen, C. B., Grauslund, M. & Santoni Rugiu, Eric, nov. 2015, I: Anticancer Research. 35, 11, s. 6223-9 7 s.

Long-term Oncologic and Financial Implications of Lung Cancer Screening

Pedersen, J. J. H. & Sørensen, Jens Benn, maj 2015, I: Thoracic Surgery Clinics. 25, 2, s. 223-9 7 s.

The prevalence of EGFR mutations in non-small cell lung cancer in an unselected Caucasian population

Skov, B. G., Høgdall, E., Clementsen, P., Krasnik, M., Larsen, Klaus Richter, Sørensen, Jens Benn, Skov, T. & Møllegaard, A., feb. 2015, I: *APMIS : acta pathologica, microbiologica, et immunologica Scandinavica*. 123, 2, s. 108-115 8 s.

Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma

Andersen, Morten, Trapani, D., Ravn, J., Sørensen, Jens Benn, Andersen, C. B., Grauslund, M. & Santoni Rugiu, Eric, 2015, I: *Anticancer Research*.

Use of TUBB3 for patient stratification and prognosis in lung cancer

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2015, I: *Lung Cancer Management*.

Use of next Generation Sequencing to Distinguish Origin of Poorly Differentiated Carcinomas in the Lung from Carcinomas in Other Organs

Sørensen, Jens Benn, Grauslund, M., Melchior, L., Urbanska, E. & Santoni Rugiu, Eric, 2015, I: *Journal of Thoracic Oncology*.

Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC)

Buhl, I. K., Christensen, I. J., Hansen, A., Jensen, T., Buhl, U. H., Brunner, N., Madsen, M. W., Sørensen, Jens Benn, Ravn, J., Santoni Rugiu, Eric, Askaa, J., Jensen, P. B. & Knudsen, S., 2015, I: *Journal of Clinical Oncology*. 33, 15, Supplement, e18502.

Diagnostic potential of miR-126, miR-143, miR-145, and miR-652 in malignant pleural mesothelioma

Andersen, M., Grauslund, M., Ravn, J., Sørensen, Jens Benn, Andersen, C. B. & Santoni Rugiu, Eric, jul. 2014, I: *The Journal of molecular diagnostics : JMD*. 16, 4, s. 418-430 13 s.

Insulin-like Growth Factor Receptor 1 mRNA Expression as a Prognostic Marker in Advanced Non-small Cell Lung Cancer

Vilmar, A., Santoni Rugiu, Eric, Cillas, J. G., Huarritz, M. & Sørensen, Jens Benn, jun. 2014, I: *Anticancer Research*. 34, 6, s. 2991-2996 6 s.

Thymidylate synthase protein expression levels remain stable during paclitaxel and carboplatin treatment in non-small cell lung cancer

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, apr. 2014, I: *Journal of Cancer Research and Clinical Oncology*. 140, 4, s. 645-652 8 s.

Differences in RRM1 protein expression between diagnostic biopsies and resection specimens, and changes during carboplatin and paclitaxel treatment, in non-small-cell lung cancer

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, feb. 2014, I: *Histopathology*. 64, 3, s. 412-420 9 s.

Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, jan. 2014, I: *Cancer Chemotherapy and Pharmacology*. 73, 1, s. 131-137 7 s.

Longitudinal assessment of TUBB3 expression in non-small cell lung cancer patients

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, jan. 2014, I: *Cancer Chemotherapy and Pharmacology*. 73, 1, s. 43-51 9 s.

Clinical impact of ki-67 labeling index in non-small cell lung cancer

Jakobsen, J. N. & Sørensen, Jens Benn, 2013, I: *Lung Cancer*. 79, 1, s. 1-7 7 s.

Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report

Rossing, H. H., Grauslund, M., Urbanska, E. M., Melchior, L. C., Rask, C., Costa, J. C., Skov, B. G., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2013, I: BMC Research Notes. 6, December, s. 1-8 8 s., 489.

Diagnostic potential of microRNAs (miRs) in malignant pleural mesothelioma (MPM)

Andersen, Morten, Grauslund, M., Ravn, J., Sørensen, Jens Benn, Andersen, C. B. & Santoni Rugiu, Eric, 2013, I: Cancer Research.

INTRATUMOR VARIATION OF BIOMARKER EXPRESSION BY IMMUNOHISTOCHEMISTRY IN RESECTABLE NON-SMALL CELL LUNG CANCER

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2013, I: Journal of Thoracic Oncology.

IS RRM1 A PREDICTIVE MARKER FOR VINOURELBINE EFFICACY - THE RESULTS FROM A COHORT OF MALIGNANT PLEURAL MESOTHELIOMAS TREATED WITH CISPLATIN AND VINOURELBINE

Zimling, Z. G., Santoni Rugiu, Eric, Bech, C. & Sørensen, Jens Benn, 2013, I: Journal of Thoracic Oncology.

Intratour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer

Jakobsen, J. N., Santoni Rugiu, Eric, Ravn, J. & Sørensen, Jens Benn, 2013, I: European journal of cancer (Oxford, England : 1990). 49, 11, s. 2494-2503 10 s.

PRETREATMENT THYMIDYLATE SYNTHASE PROTEIN EXPRESSION LEVELS REMAINS STABLE DURING PACLITAXEL AND CARBOPLATIN TREATMENT IN NON-SMALL CELL LUNG CANCER

Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2013, I: Journal of Thoracic Oncology.

Platinum-based doublet chemotherapy plus bevacizumab without bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC)

Nørøxe, D. S., Wallerek, S. & Sørensen, Jens Benn, 2013, I: Anticancer Research. 33, 8, s. 3275-3278 4 s.

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial

Vilmar, A. C., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2013, I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 24, 2, s. 309-14 6 s.

RRM1 protein expression heterogeneity between diagnostic biopsies and resection specimens and changes in expression during carboplatin and paclitaxel treatment in non-small cell lung cancer

Jakobsen, J., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2013, I: European Journal of Cancer.

A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma

Zimling, Z. G., Sørensen, Jens Benn, Gerds, Thomas Alexander, Bech, C., Andersen, C. B. & Santoni Rugiu, Eric, nov. 2012, I: Cancer Chemotherapy and Pharmacology. 70, 5, s. 743-54 12 s.

5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity

Jensen, S. A. & Sørensen, Jens Benn, 2012, I: Cancer Chemotherapy and Pharmacology. 69, 1, s. 57-64 8 s.

A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant plural mesothelioma

Zimling, Z. G., Sørensen, Jens Benn, Gerds, Thomas Alexander, Bech, C., Andersen, C. B. & Santoni-Rugiu, E., 2012, I: Cancer Chemotherapy and Pharmacology. 70, 5, s. 743-754 12 s.

Are differentially expressed microRNAs useful in the diagnostics of malignant pleural mesothelioma?

Andersen, M., Grauslund, M., Muhammad-Ali, M., Ravn, J., Sørensen, Jens Benn, Andersen, C. B. & Santoni Rugiu, Eric, 2012, I: A P M I S. Acta Pathologica, Microbiologica et Immunologica Scandinavica. 120, 9, s. 767-9 3 s.

Carcinoembryonic antigen (CEA) as tumor marker in lung cancer

Knudsen, M. G. & Sørensen, Jens Benn, 2012, I: Lung Cancer. 76, 2, s. 138-43 6 s.

Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer
Jakobsen, J. N. & Sørensen, Jens Benn, 2012, I: Cancer Chemotherapy and Pharmacology. 69, 2, s. 289-99 11 s.

Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival
Zimling, Z. G., Sørensen, Jens Benn, Gerds, Thomas Alexander, Bech, C., Andersen, C. B. & Santoni Rugiu, Eric, 2012, I: Journal of Thoracic Oncology. 7, 1, s. 249-56 8 s.

PROGNOSTIC AND PREDICTIVE IMPACT OF KI-67 INDEX IN NEO-ADJUVANT CHEMOTHERAPY BEFORE SURGERY IN NON-SMALL CELL LUNG CANCER
Jakobsen, J. N., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2012, I: Annals of Oncology.

Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomized in a chemotherapy phase III trial
Vilmar, A., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2012, I: Journal of Clinical Oncology.

RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC
Vilmar, A. C., Garcia-Foncillas, J., Huariz, M., Santoni Rugiu, Eric, Sørensen, Jens Benn & Vilmar, A. C., 2012, I: Lung Cancer. 75, 3, s. 306-12 7 s.

Second-line Oral Vinorelbine Following First-Line Platinum and Pemetrexed in Malignant Pleural Mesothelioma
Sørensen, Jens Benn, Langer, S. W., Urbanska, E. & Aamdal, E., 2012, I: European Journal of Clinical & Medical Oncology. 4, 4, s. 1-7

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas
Olsen, I. M. H., Sørensen, Jens Benn, Federspiel, B., Kjær, Andreas, Hansen, C. P., Knigge, Ulrich & Langer, S. W., 2012, I: Scientific World Journal. 2012, s. 170496 4 s.

Ultra-late relapse with a single cerebellar metastasis 10 years after complete surgery for stage IIA non-small cell lung cancer (bronchioalveolar carcinoma)
Nørøxe, D. S. & Sørensen, Jens Benn, 2012, I: Journal of Thoracic Oncology. 7, 4, s. 764-5 2 s.

Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010
Felip, E., Gridelli, C., Baas, P., Rosell, R., Stahel, R., Sørensen, Jens Benn & Panel Members, P. M., jul. 2011, I: Annals of Oncology. 22, 7, s. 1507-19 13 s.

Pharmacokinetic evaluation of pemetrexed
Sørensen, Jens Benn, jul. 2011, I: Expert Opinion on Drug Metabolism & Toxicology. 7, 7, s. 919-28 10 s.

Review on clinical trials of targeted treatments in malignant mesothelioma
Jakobsen, J. N. & Sørensen, Jens Benn, jul. 2011, I: Cancer Chemotherapy and Pharmacology. 68, 1, s. 1-15 15 s.

Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Vilmar, A. C. & Sørensen, Jens Benn, mar. 2011, I: European Respiratory Journal. 20, 119, s. 45-52 8 s.

1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer
Stahel, R., Thatcher, N., Früh, M., Le Péchoux, C., Postmus, P. E., Sørensen, Jens Benn, Felip, E. & Panel members, P. M., 2011, I: Annals of Oncology. 22, 9, s. 1973-80 8 s.

AN IMMUNOHISTOCHEMICAL PROFILE FOR PREDICTING RESPONSE TO CISPLATIN/VINORELBINE THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA
Zimling, Z. G., Bech, C., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2011, I: Journal of Thoracic Oncology.

CLASS III beta-TUBULIN, HISTOPATHOLOGY AND QUALITY OF LIFE IN ADVANCED NSCLC PATIENTS RANDOMIZED IN A LARGE MULTICENTER PHASE III TRIAL

Vilmar, A., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2011, I: Journal of Thoracic Oncology.

Class III beta-Tubulin in Advanced NSCLC of Adenocarcinoma Subtype Predicts Superior Outcome in a Randomized Trial
Vilmar, A. C., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2011, I: Clinical Cancer Research.

Class III β -tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial
Vilmar, A. C., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2011, I: Clinical Cancer Research. 17, 15, s. 5205-14 10 s.

Immunohistochemical detection of ERCC1 and class III beta-tubulin in 54 malignant pleural mesotheliomas treated with cisplatin and vinorelbine: association with treatment response and survival
Zimling, Z. G., Bech, C., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2011, I: APMIS.

Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin
Afzal, Shoaib, Jensen, S. A., Sørensen, Jens Benn, Henriksen, T., Weimann, A. & Poulsen, Henrik Enghusen, 2011, I: Cancer Chemotherapy and Pharmacology. 69, s. 301-307

RT-PCR VERSUS IMMUNOHISTOCHEMISTRY FOR CORRELATION AND QUANTIFICATION OF ERCC1, BRCA1, TUBB3 & RRM1 IN NSCLC

Vilmar, A., Garcia-Focillas, J., Huarritz, M., Santoni Rugiu, Eric & Sørensen, Jens Benn, 2011, I: Journal of Thoracic Oncology.

Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle

Jensen, S. A., Hasbak, P., Mortensen, Jann & Sørensen, Jens Benn, 20 dec. 2010, I: Journal of Clinical Oncology. 28, 36, s. 5280-6 7 s.

Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells—associations with histopathology and patients outcome

Jensen, S. A., Vainer, B., Bartels, A., Brünner, N. A. & Sørensen, Jens Benn, 1 dec. 2010, I: European Journal of Cancer. 46, 18, s. 3233-42 10 s.

Diagnostik af malignt pleuralt mesoteliom

Sørensen, Jens Benn, 27 sep. 2010, I: Ugeskrift for Laeger. 172, 39, s. 2669

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

Vilmar, A. C., Santoni Rugiu, Eric & Sørensen, Jens Benn, 1 sep. 2010, I: Annals of Oncology. 21, 9, s. 1817-24 8 s.

ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial

Vilmar, A. C., Santoni Rugiu, Eric & Sørensen, Jens Benn, 1 jun. 2010, I: European Journal of Cancer. 46, 9, s. 1554-62 9 s.

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Dickgreber, N. J., Sørensen, Jens Benn, Paz-Ares, L. G., Schytte, T. K., Latz, J. E., Schneck, K. B., Zheng, Y. & Sanchez-Torres, J. M., 15 maj 2010, I: Clinical Cancer Research. 16, 10, s. 2872-80 9 s.

Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: a review and case report

Bech, C. & Sørensen, Jens Benn, 1 maj 2010, I: Journal of Thoracic Oncology. 5, 5, s. 735-40 6 s.

Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP)

Stahel, R., Baas, P., Faivre-Finn, C., Dooms, C., Passlick, B., Mazières, J., Cappuzzo, F., Früh, M., Sørensen, Jens Benn, Blackhall, F., Taron, M., Gridelli, C., O'Byrne, K. & Rosell, R., 1 apr. 2010, I: Lung Cancer. 68, 1, s. 121-4 4 s.

Hjertepåvirkning fra 5-fluorouracil og capecitabin

Jensen, S. A., Jensen, L. B., Petersen, L. N., Reiter, L. & Sørensen, Jens Benn, 4 jan. 2010, I: Ugeskrift for Læger. 172, 1, s. 48-51 4 s.

Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells—associations with histopathology and patients outcome

Jensen, S. A., Vainer, B., Bartels, Annette Snebjerg, Brünner, N. & Sørensen, Jens Benn, 2010, I: European journal of cancer (Oxford, England : 1990). 46, 18, s. 3233-42 10 s.

Immunohistochemical Detection of Erccl and Class III beta-tubulin in 54 Malignant Pleural Mesotheliomas Treated With Cisplatin and Vinorelbine: Association With Treatment Response and Survival

Zimling, Z. G., Bech, C., Sørensen, Jens Benn & Santoni Rugiu, Eric, 2010, I: Journal of Thoracic Oncology.

Impact of the excision repair cross-complementation group 1 predictive biomarker on toxicity and quality of life in advanced non-small cell lung cancer patients randomized in a large, multicenter, cisplatin-based phase III trial

Santoni Rugiu, Eric, Vilmar, A. & Sørensen, Jens Benn, 2010, I: Virchows Archiv.

Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel

De Marinis, F., Eberhardt, W., Harper, P. G., Sureda, B. M., Nackaerts, K., Sørensen, Jens Benn, Syrigos, K. & Trédaniel, J., 2009, I: Journal of Thoracic Oncology. 4, 10, s. 1280-8 8 s.

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression

Jensen, S. A., Vainer, B., Kruhøffer, M. & Sørensen, Jens Benn, 2009, I: BMC Cancer. 9, s. 25

Screening for asbestbetingede sygdomme?

Brauer, C., Baandrup, U., Jacobsen, P., Krasnik, M., Olsen, J. H., Pedersen, J. H., Rasmussen, T. R., Schlünssen, V., Sherson, D., Svolgaard, B., Sørensen, Jens Benn & Omland, O., 2009, I: Ugeskrift for læger. 171, 6, s. 433-6 4 s.

The effect of n-3-fatty acids on quality of life in patients with lung cancer

Møller, G., Nørgaard, M., Dannerfjord, S. H., Lauritzen, Lotte, Sørensen, Jens Benn, Lange, P., Jensen, N. A., Boisen, L. W., Jensen, Ramon Gordon, Andersen, M. & Andersen, Jens Rikardt, 2009, *18. årsmøde i klinisk ernæring: Århus, 2009*. s. 25 1 s.

The effect of n-3-fatty acids on quality of life in patients with lung cancer

Møller, G., Nørgaard, M., Dannerfjord, S. H., Lauritzen, Lotte, Sørensen, Jens Benn, Lange, Peter, Jensen, N., Boisen, L. W., Jensen, R. G., Andersen, M. & Andersen, Jens Rikardt, 2009, I: Journal of Parenteral and Enteral Nutrition. 33, 2, s. 215 1 s.

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

Frank, H., Palshof, T. & Sørensen, Jens Benn, 2008, I: British Journal of Cancer. 99, 1, s. 44-50 6 s.

Current concepts in chemotherapy for malignant pleural mesothelioma

Sorensen, J. B. & Sørensen, Jens Benn, 2008, I: Clinical Respiratory Journal. 2, s. 74-79 5 s.

Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies

Skovsgaard, T., Bork, E., Damstrup, L., Ingeberg, S. & Sørensen, Jens Benn, 2008, I: Cancer. 112, 7, s. 1600-1606 6 s.

Exercise on prescription: a randomized study on the effect of counseling vs counseling and supervised exercise

Kragstrup, J., Skovsgaard, T., Puggaard, L. & Sørensen, Jens Benn, 2008, I: Scandinavian Journal of Medicine & Science in Sports. 18, 3, s. 288-297 9 s.

Outpatient management of febrile neutropenia: time to revise the present treatment strategy

Carstensen, M. & Sørensen, Jens Benn, 2008, I: Journal of Supportive Oncology. 6, 5, s. 199-208 9 s.

Polyneuropathy in a patient with malignant pleural mesothelioma: a paraneoplastic syndrome

Bech, C. & Sørensen, Jens Benn, 2008, I: Journal of Thoracic Oncology. 3, 11, s. 1359-1360 1 s.

Prognostic significance of numeric aberrations of genes for thymidylate synthase, thymidine phosphorylase and dihydrofolate reductase in colorectal cancer

Jensen, S. A., Vainer, B., Witton, C. J., Jørgensen, J. T. & Sørensen, Jens Benn, 2008, I: Acta Oncologica. 47, 6, s. 1054-1061 7 s.

Third-line therapy for metastatic colorectal cancer

Gundgaard, M. G., Ehrnrooth, E. & Sørensen, Jens Benn, 2008, I: Cancer Chemotherapy and Pharmacology. 61, 1, s. 1-13 12 s.

Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study

Hillerdal, G., Sundstrom, S., Riska, H., Vikstrom, A., Hjerpe, A. & Sørensen, Jens Benn, 2008, I: Journal of Thoracic Oncology. 3, 11, s. 1325-1331 6 s.

Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study

Hillerdal, G., Sundstrom, S., Vikstrom, A., Hjerpe, A. & Sørensen, Jens Benn, 2008, I: Clinical Respiratory Journal. 3, s. 80-85 5 s.

Brain relapses in chemotherapy-treated small cell lung cancer: A retrospective review of two time-dose regimens of therapeutic brain irradiation

Bach, F., Sørensen, Jens Benn, Adrian, L., Larsen, H., Langer, Seppo W., Nelausen, K. M. & Engelholm, S. A., sep. 1996, I: Lung Cancer. 15, 2, s. 171-181 11 s.